APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Lacosamide

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Lacosamide Market Analysis and Forecast 2026-2032

Report ID 174006220222 December 2025195 pages

Choose your research edition.

Industry ResearchLacosamide Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Lacosamide Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Lacosamide Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Lacosamide Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Lacosamide Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Lacosamide market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Lacosamide is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Lacosamide is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Lacosamide is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Lacosamide is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Lacosamide include UCB, Teva, Sun Pharma, Mylan, MSN Laboratories, Glenmark, Aurobindo Pharma, Apotex and Amneal Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Lacosamide, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Lacosamide, also provides the revenue of main regions and countries. Of the upcoming market potential for Lacosamide, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Lacosamide revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Lacosamide market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Lacosamide revenue, projected growth trends, production technology, application and end-user industry.

Lacosamide Segment by Company

UCB

Teva

Sun Pharma

Mylan

MSN Laboratories

Glenmark

Aurobindo Pharma

Apotex

Amneal Pharmaceuticals

Alembic Pharma

Accord Healthcare

Lacosamide Segment by Type

Intravenous

Oral tablets

Oral solution

Lacosamide Segment by Application

Adults

Pediatric patients

Lacosamide Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lacosamide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Lacosamide and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lacosamide.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Lacosamide in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Lacosamide company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Lacosamide revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Lacosamide Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Intravenous Major Player Table 3. Oral tablets Major Player Table 4. Oral solution Major Player Table 5. Global Lacosamide Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Adults Major Player Table 7. Pediatric patients Major Player Table 8. Lacosamide Industry Trends Table 9. Lacosamide Industry Drivers Table 10. Lacosamide Industry Opportunities and Challenges Table 11. Lacosamide Industry Restraints Table 12. Global Lacosamide Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Lacosamide Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Lacosamide Market Share by Region (2021-2026) Table 15. Global Lacosamide Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Lacosamide Market Share by Region (2027-2032) Table 17. Global Lacosamide Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Lacosamide Revenue Market Share by Players (2021-2026) Table 19. Global Lacosamide Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Lacosamide Key Players Headquarters & Area Served Table 21. Global Lacosamide Players, Product Type & Application Table 22. Global Lacosamide Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Lacosamide by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Lacosamide Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Lacosamide Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Lacosamide Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Lacosamide Revenue Market Share by Type (2021-2026) Table 29. Global Lacosamide Revenue Market Share by Type (2027-2032) Table 30. Global Lacosamide Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Lacosamide Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Lacosamide Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Lacosamide Revenue Market Share by Application (2021-2026) Table 34. Global Lacosamide Revenue Market Share by Application (2027-2032) Table 35. UCB Company Information Table 36. UCB Business Overview Table 37. UCB Lacosamide Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. UCB Lacosamide Product Portfolio Table 39. UCB Recent Development Table 40. Teva Company Information Table 41. Teva Business Overview Table 42. Teva Lacosamide Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Teva Lacosamide Product Portfolio Table 44. Teva Recent Development Table 45. Sun Pharma Company Information Table 46. Sun Pharma Business Overview Table 47. Sun Pharma Lacosamide Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Sun Pharma Lacosamide Product Portfolio Table 49. Sun Pharma Recent Development Table 50. Mylan Company Information Table 51. Mylan Business Overview Table 52. Mylan Lacosamide Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Mylan Lacosamide Product Portfolio Table 54. Mylan Recent Development Table 55. MSN Laboratories Company Information Table 56. MSN Laboratories Business Overview Table 57. MSN Laboratories Lacosamide Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. MSN Laboratories Lacosamide Product Portfolio Table 59. MSN Laboratories Recent Development Table 60. Glenmark Company Information Table 61. Glenmark Business Overview Table 62. Glenmark Lacosamide Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Glenmark Lacosamide Product Portfolio Table 64. Glenmark Recent Development Table 65. Aurobindo Pharma Company Information Table 66. Aurobindo Pharma Business Overview Table 67. Aurobindo Pharma Lacosamide Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Aurobindo Pharma Lacosamide Product Portfolio Table 69. Aurobindo Pharma Recent Development Table 70. Apotex Company Information Table 71. Apotex Business Overview Table 72. Apotex Lacosamide Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Apotex Lacosamide Product Portfolio Table 74. Apotex Recent Development Table 75. Amneal Pharmaceuticals Company Information Table 76. Amneal Pharmaceuticals Business Overview Table 77. Amneal Pharmaceuticals Lacosamide Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Amneal Pharmaceuticals Lacosamide Product Portfolio Table 79. Amneal Pharmaceuticals Recent Development Table 80. Alembic Pharma Company Information Table 81. Alembic Pharma Business Overview Table 82. Alembic Pharma Lacosamide Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Alembic Pharma Lacosamide Product Portfolio Table 84. Alembic Pharma Recent Development Table 85. Accord Healthcare Company Information Table 86. Accord Healthcare Business Overview Table 87. Accord Healthcare Lacosamide Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. Accord Healthcare Lacosamide Product Portfolio Table 89. Accord Healthcare Recent Development Table 90. North America Lacosamide Revenue by Type (2021-2026) & (US$ Million) Table 91. North America Lacosamide Revenue by Type (2027-2032) & (US$ Million) Table 92. North America Lacosamide Revenue by Application (2021-2026) & (US$ Million) Table 93. North America Lacosamide Revenue by Application (2027-2032) & (US$ Million) Table 94. North America Lacosamide Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 95. North America Lacosamide Revenue by Country (2021-2026) & (US$ Million) Table 96. North America Lacosamide Revenue by Country (US$ Million) & (2027-2032) Table 97. Europe Lacosamide Revenue by Type (2021-2026) & (US$ Million) Table 98. Europe Lacosamide Revenue by Type (2027-2032) & (US$ Million) Table 99. Europe Lacosamide Revenue by Application (2021-2026) & (US$ Million) Table 100. Europe Lacosamide Revenue by Application (2027-2032) & (US$ Million) Table 101. Europe Lacosamide Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 102. Europe Lacosamide Revenue by Country (2021-2026) & (US$ Million) Table 103. Europe Lacosamide Revenue by Country (US$ Million) & (2027-2032) Table 104. China Lacosamide Revenue by Type (2021-2026) & (US$ Million) Table 105. China Lacosamide Revenue by Type (2027-2032) & (US$ Million) Table 106. China Lacosamide Revenue by Application (2021-2026) & (US$ Million) Table 107. China Lacosamide Revenue by Application (2027-2032) & (US$ Million) Table 108. Asia Lacosamide Revenue by Type (2021-2026) & (US$ Million) Table 109. Asia Lacosamide Revenue by Type (2027-2032) & (US$ Million) Table 110. Asia Lacosamide Revenue by Application (2021-2026) & (US$ Million) Table 111. Asia Lacosamide Revenue by Application (2027-2032) & (US$ Million) Table 112. Asia Lacosamide Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 113. Asia Lacosamide Revenue by Region (US$ Million) & (2021-2026) Table 114. Asia Lacosamide Revenue by Region (US$ Million) & (2027-2032) Table 115. SAMEA Lacosamide Revenue by Type (2021-2026) & (US$ Million) Table 116. SAMEA Lacosamide Revenue by Type (2027-2032) & (US$ Million) Table 117. SAMEA Lacosamide Revenue by Application (2021-2026) & (US$ Million) Table 118. SAMEA Lacosamide Revenue by Application (2027-2032) & (US$ Million) Table 119. SAMEA Lacosamide Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. SAMEA Lacosamide Revenue by Country (2021-2026) & (US$ Million) Table 121. SAMEA Lacosamide Revenue by Country (US$ Million) & (2027-2032) Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. Lacosamide Image Figure 2. Global Lacosamide Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Lacosamide Market Size Share 2021 VS 2025 VS 2032 Figure 4. Intravenous Image Figure 5. Oral tablets Image Figure 6. Oral solution Image Figure 7. Global Lacosamide Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Lacosamide Market Size Share 2021 VS 2025 VS 2032 Figure 9. Adults Image Figure 10. Pediatric patients Image Figure 11. Global Lacosamide Market Size (US$ Million) & (2021-2032) Figure 12. Global Lacosamide Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Lacosamide Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Lacosamide Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Lacosamide Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Lacosamide Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Lacosamide Revenue Market Share by Type (2021-2032) Figure 19. Global Lacosamide Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Lacosamide Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Lacosamide Revenue Market Share by Application (2021-2032) Figure 22. North America Lacosamide Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Lacosamide Revenue Share by Type (2021-2032) Figure 24. North America Lacosamide Revenue Share by Application (2021-2032) Figure 25. North America Lacosamide Revenue Share by Country (2021-2032) Figure 26. United States Lacosamide Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Lacosamide Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Lacosamide Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Lacosamide Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Lacosamide Revenue Share by Type (2021-2032) Figure 31. Europe Lacosamide Revenue Share by Application (2021-2032) Figure 32. Europe Lacosamide Revenue Share by Country (2021-2032) Figure 33. Germany Lacosamide Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Lacosamide Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Lacosamide Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Lacosamide Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Lacosamide Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Lacosamide Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Lacosamide Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Lacosamide Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Lacosamide Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Lacosamide Revenue Share by Type (2021-2032) Figure 43. China Lacosamide Revenue Share by Application (2021-2032) Figure 44. Asia Lacosamide Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Lacosamide Revenue Share by Type (2021-2032) Figure 46. Asia Lacosamide Revenue Share by Application (2021-2032) Figure 47. Asia Lacosamide Revenue Share by Region (2021-2032) Figure 48. Japan Lacosamide Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Lacosamide Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Lacosamide Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Lacosamide Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Lacosamide Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Lacosamide Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Lacosamide Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Lacosamide Revenue Share by Type (2021-2032) Figure 56. SAMEA Lacosamide Revenue Share by Application (2021-2032) Figure 57. SAMEA Lacosamide Revenue Share by Country (2021-2032) Figure 58. Brazil Lacosamide Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Lacosamide Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Lacosamide Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Lacosamide Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Lacosamide Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Lacosamide Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Lacosamide Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Lacosamide Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Lacosamide Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Lacosamide Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Lacosamide Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Intravenous
  • Oral tablets
  • Oral solution
Applications
  • Adults
  • Pediatric patients
Companies covered
  • UCB
  • Teva
  • Sun Pharma
  • Mylan
  • MSN Laboratories
  • Glenmark
  • Aurobindo Pharma
  • Apotex
  • Amneal Pharmaceuticals
  • Alembic Pharma
  • Accord Healthcare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Lacosamide Market by Type
  3. 1.2.1 Global Lacosamide Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Intravenous
  5. 1.2.3 Oral tablets
  6. 1.2.4 Oral solution
  7. 1.3 Lacosamide Market by Application
  8. 1.3.1 Global Lacosamide Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Adults
  10. 1.3.3 Pediatric patients
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Lacosamide Market Dynamics
  1. 2.1 Lacosamide Industry Trends
  2. 2.2 Lacosamide Industry Drivers
  3. 2.3 Lacosamide Industry Opportunities and Challenges
  4. 2.4 Lacosamide Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Lacosamide Market Perspective (2021-2032)
  2. 3.2 Global Lacosamide Growth Trends by Region
  3. 3.2.1 Global Lacosamide Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Lacosamide Market Size by Region (2021-2026)
  5. 3.2.3 Global Lacosamide Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Lacosamide Revenue by Players
  2. 4.1.1 Global Lacosamide Revenue by Players (2021-2026)
  3. 4.1.2 Global Lacosamide Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Lacosamide Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Lacosamide Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Lacosamide Key Players Headquarters & Area Served
  7. 4.4 Global Lacosamide Players, Product Type & Application
  8. 4.5 Global Lacosamide Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Lacosamide Market CR5 and HHI
  11. 4.6.3 2025 Lacosamide Tier 1, Tier 2, and Tier 3
5 Lacosamide Market Size by Type
  1. 5.1 Global Lacosamide Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Lacosamide Revenue by Type (2021-2032)
  3. 5.3 Global Lacosamide Revenue Market Share by Type (2021-2032)
6 Lacosamide Market Size by Application
  1. 6.1 Global Lacosamide Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Lacosamide Revenue by Application (2021-2032)
  3. 6.3 Global Lacosamide Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 UCB
  2. 7.1.1 UCB Company Information
  3. 7.1.2 UCB Business Overview
  4. 7.1.3 UCB Lacosamide Revenue and Gross Margin (2021-2026)
  5. 7.1.4 UCB Lacosamide Product Portfolio
  6. 7.1.5 UCB Recent Developments
  7. 7.2 Teva
  8. 7.2.1 Teva Company Information
  9. 7.2.2 Teva Business Overview
  10. 7.2.3 Teva Lacosamide Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Teva Lacosamide Product Portfolio
  12. 7.2.5 Teva Recent Developments
  13. 7.3 Sun Pharma
  14. 7.3.1 Sun Pharma Company Information
  15. 7.3.2 Sun Pharma Business Overview
  16. 7.3.3 Sun Pharma Lacosamide Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sun Pharma Lacosamide Product Portfolio
  18. 7.3.5 Sun Pharma Recent Developments
  19. 7.4 Mylan
  20. 7.4.1 Mylan Company Information
  21. 7.4.2 Mylan Business Overview
  22. 7.4.3 Mylan Lacosamide Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Mylan Lacosamide Product Portfolio
  24. 7.4.5 Mylan Recent Developments
  25. 7.5 MSN Laboratories
  26. 7.5.1 MSN Laboratories Company Information
  27. 7.5.2 MSN Laboratories Business Overview
  28. 7.5.3 MSN Laboratories Lacosamide Revenue and Gross Margin (2021-2026)
  29. 7.5.4 MSN Laboratories Lacosamide Product Portfolio
  30. 7.5.5 MSN Laboratories Recent Developments
  31. 7.6 Glenmark
  32. 7.6.1 Glenmark Company Information
  33. 7.6.2 Glenmark Business Overview
  34. 7.6.3 Glenmark Lacosamide Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Glenmark Lacosamide Product Portfolio
  36. 7.6.5 Glenmark Recent Developments
  37. 7.7 Aurobindo Pharma
  38. 7.7.1 Aurobindo Pharma Company Information
  39. 7.7.2 Aurobindo Pharma Business Overview
  40. 7.7.3 Aurobindo Pharma Lacosamide Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Aurobindo Pharma Lacosamide Product Portfolio
  42. 7.7.5 Aurobindo Pharma Recent Developments
  43. 7.8 Apotex
  44. 7.8.1 Apotex Company Information
  45. 7.8.2 Apotex Business Overview
  46. 7.8.3 Apotex Lacosamide Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Apotex Lacosamide Product Portfolio
  48. 7.8.5 Apotex Recent Developments
  49. 7.9 Amneal Pharmaceuticals
  50. 7.9.1 Amneal Pharmaceuticals Company Information
  51. 7.9.2 Amneal Pharmaceuticals Business Overview
  52. 7.9.3 Amneal Pharmaceuticals Lacosamide Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Amneal Pharmaceuticals Lacosamide Product Portfolio
  54. 7.9.5 Amneal Pharmaceuticals Recent Developments
  55. 7.10 Alembic Pharma
  56. 7.10.1 Alembic Pharma Company Information
  57. 7.10.2 Alembic Pharma Business Overview
  58. 7.10.3 Alembic Pharma Lacosamide Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Alembic Pharma Lacosamide Product Portfolio
  60. 7.10.5 Alembic Pharma Recent Developments
  61. 7.11 Accord Healthcare
  62. 7.11.1 Accord Healthcare Company Information
  63. 7.11.2 Accord Healthcare Business Overview
  64. 7.11.3 Accord Healthcare Lacosamide Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Accord Healthcare Lacosamide Product Portfolio
  66. 7.11.5 Accord Healthcare Recent Developments
8 North America
  1. 8.1 North America Lacosamide Revenue (2021-2032)
  2. 8.2 North America Lacosamide Revenue by Type (2021-2032)
  3. 8.2.1 North America Lacosamide Revenue by Type (2021-2026)
  4. 8.2.2 North America Lacosamide Revenue by Type (2027-2032)
  5. 8.3 North America Lacosamide Revenue Share by Type (2021-2032)
  6. 8.4 North America Lacosamide Revenue by Application (2021-2032)
  7. 8.4.1 North America Lacosamide Revenue by Application (2021-2026)
  8. 8.4.2 North America Lacosamide Revenue by Application (2027-2032)
  9. 8.5 North America Lacosamide Revenue Share by Application (2021-2032)
  10. 8.6 North America Lacosamide Revenue by Country
  11. 8.6.1 North America Lacosamide Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Lacosamide Revenue by Country (2021-2026)
  13. 8.6.3 North America Lacosamide Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Lacosamide Revenue (2021-2032)
  2. 9.2 Europe Lacosamide Revenue by Type (2021-2032)
  3. 9.2.1 Europe Lacosamide Revenue by Type (2021-2026)
  4. 9.2.2 Europe Lacosamide Revenue by Type (2027-2032)
  5. 9.3 Europe Lacosamide Revenue Share by Type (2021-2032)
  6. 9.4 Europe Lacosamide Revenue by Application (2021-2032)
  7. 9.4.1 Europe Lacosamide Revenue by Application (2021-2026)
  8. 9.4.2 Europe Lacosamide Revenue by Application (2027-2032)
  9. 9.5 Europe Lacosamide Revenue Share by Application (2021-2032)
  10. 9.6 Europe Lacosamide Revenue by Country
  11. 9.6.1 Europe Lacosamide Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Lacosamide Revenue by Country (2021-2026)
  13. 9.6.3 Europe Lacosamide Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Lacosamide Revenue (2021-2032)
  2. 10.2 China Lacosamide Revenue by Type (2021-2032)
  3. 10.2.1 China Lacosamide Revenue by Type (2021-2026)
  4. 10.2.2 China Lacosamide Revenue by Type (2027-2032)
  5. 10.3 China Lacosamide Revenue Share by Type (2021-2032)
  6. 10.4 China Lacosamide Revenue by Application (2021-2032)
  7. 10.4.1 China Lacosamide Revenue by Application (2021-2026)
  8. 10.4.2 China Lacosamide Revenue by Application (2027-2032)
  9. 10.5 China Lacosamide Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Lacosamide Revenue (2021-2032)
  2. 11.2 Asia Lacosamide Revenue by Type (2021-2032)
  3. 11.2.1 Asia Lacosamide Revenue by Type (2021-2026)
  4. 11.2.2 Asia Lacosamide Revenue by Type (2027-2032)
  5. 11.3 Asia Lacosamide Revenue Share by Type (2021-2032)
  6. 11.4 Asia Lacosamide Revenue by Application (2021-2032)
  7. 11.4.1 Asia Lacosamide Revenue by Application (2021-2026)
  8. 11.4.2 Asia Lacosamide Revenue by Application (2027-2032)
  9. 11.5 Asia Lacosamide Revenue Share by Application (2021-2032)
  10. 11.6 Asia Lacosamide Revenue by Country
  11. 11.6.1 Asia Lacosamide Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Lacosamide Revenue by Country (2021-2026)
  13. 11.6.3 Asia Lacosamide Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Lacosamide Revenue (2021-2032)
  2. 12.2 SAMEA Lacosamide Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Lacosamide Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Lacosamide Revenue by Type (2027-2032)
  5. 12.3 SAMEA Lacosamide Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Lacosamide Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Lacosamide Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Lacosamide Revenue by Application (2027-2032)
  9. 12.5 SAMEA Lacosamide Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Lacosamide Revenue by Country
  11. 12.6.1 SAMEA Lacosamide Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Lacosamide Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Lacosamide Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst